Nom du produit:Methyl 3-Amino-2-Chloro-6-Fluorobenzoate

IUPAC Name:methyl 3-amino-2-chloro-6-fluorobenzoate

CAS:1268830-74-5
Formule moléculaire:C8H7ClFNO2
Pureté:95%+
Numéro de catalogue:CM448010
Poids moléculaire:203.6

Unité d'emballage Stock disponible Prix($) Quantité
CM448010-100mg 3-4 Weeks ŵǜƦ
CM448010-250mg 3-4 Weeks ǶƦNJ
CM448010-1g 4-5 Weeks ǜưǶ
CM448010-5g 5-6 Weeks ŵưȡũ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:1268830-74-5
Formule moléculaire:C8H7ClFNO2
Point de fusion:-
Code SMILES:COC(=O)C1=C(Cl)C(N)=CC=C1F
Densité:
Numéro de catalogue:CM448010
Poids moléculaire:203.6
Point d'ébullition:
N° Mdl:MFCD24646162
Stockage:

Column Infos

Tinlorafenib
The Journal of Medicinal Chemistry releases an article titled "Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer". Mutations in the BRAF gene result in MAPK pathway activation that are most commonly found in human melanomas. The BRAF V600E mutation is among the most frequent types. Present BRAF inhibitors have significantly improved treatment outcomes for patients with BRAF V600-mutant cancers. However, their effectiveness is limited by disease progression in the brain as they don’t adequately penetrate the blood-brain barrier (BBB).
Pfizer’s Tinlorafenib (formerly PF 07284890) is a highly brain-penetrant inhibitor of BRAF V600-mutant tumors, and currently in a phase 1 clinical trial (NCT04543188). 

Related Products